S&P 500 7,561.67 −0.40%
Nasdaq 25,136.27 −0.91%
S&P/TSX 36,105.90 −0.09%
Apple 356.27 +0.39%
Nvidia 162.85 −2.01%
Microsoft 523.88 +0.17%
Shopify 209.74 +0.16%
Royal Bank 288.37 −0.35%
CAD/USD 0.7008 −0.06%
CLOSED · 13:55 ET
Market ClerkRecap
Sat Nov 14 · markets closed3 signals today368 insider buys this week · $138.2MCIRO short report next: Nov 15The week ahead

REPL

Replimune Group, Inc.
NASDAQ · HEALTH CARE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
21.98
+0.20 +0.92%
USD · Nov 12, 06:40 p.m. ET

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Financials

SEC XBRL · 48 PERIODS · WHOLE USD

By quarter

PeriodRevenueYoYGross marginOperating incomeNet incomeYoYEPSOp. cash flowCapexFree cash flowFiled
Q2 2027 · Sep 30———−$56.3M−$57.1M—-0.54−$47.7M$77K−$47.8MOct 28
Q1 2027 · Jun 30———−$68.2M−$69.8M—-0.72−$75.7M$6K−$75.7MOct 28
Q4 2026 · Mar 31derived———−$73.3M−$73.2M—-0.76−$56.2M$5K−$56.2MJun 29
Q3 2026 · Dec 31———−$71.9M−$70.9M—-0.77−$66M$135K−$66.1MFeb 3
Q2 2026 · Sep 30———−$84.3M−$83.1M—-0.90−$81.2M$1.3M−$82.6MOct 28
Q1 2026 · Jun 30———−$90.4M−$86.7M—-0.95−$77M$2.7M−$79.8MOct 28
Q4 2025 · Mar 31derived———−$79.3M−$74.1M—-0.82−$53.7M$1.1M−$54.9MJun 29
Q3 2025 · Dec 31———−$66M−$66.3M—-0.79−$50.7M$1.8M−$52.5MFeb 3
Q2 2025 · Sep 30———−$58.9M−$53.1M—-0.68−$38.6M$2.1M−$40.7MFeb 3
Q1 2025 · Jun 30———−$57.4M−$53.8M—-0.78−$49.2M$1.7M−$50.8MFeb 3
Q4 2024 · Mar 31derived———−$58.8M−$55.1M—-0.82−$46.2M$1.7M−$47.9MMay 22
Q3 2024 · Dec 31———−$56.5M−$51.1M—-0.77−$47.1M$1.7M−$48.8MFeb 12

By fiscal year

YearRevenueGross marginOperating incomeNet incomeNet marginEPSOp. cash flowCapexFree cash flowBuybacksDividends paid
FY2026 · to Mar 31——−$319.9M−$313.9M—-3.38−$280.3M$4.2M−$284.6M——
FY2025 · to Mar 31——−$261.6M−$247.3M—-3.07−$192.3M$6.7M−$198.9M——
FY2024 · to Mar 31——−$234.8M−$215.8M—-3.24−$185.5M$5.7M−$191.1M——
FY2023 · to Mar 31——−$177.1M−$174.3M—-2.99−$128.1M$2.3M−$130.3M——
FY2022 · to Mar 31——−$118.3M−$118M—-2.26−$82.2M$2.3M−$84.5M——
FY2021 · to Mar 31——−$80M−$80.9M—-1.75−$61.4M$2.4M−$63.8M——

Every number comes from Replimune Group, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.

Watch REPL. Know when insiders buy.
One email the day a filing lands. Free.